• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内源性逆转录元件适应产生的可溶性 PD-L1 是一种受体拮抗剂。

Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist.

机构信息

Retroviral Immunology, The Francis Crick Institute, London, United Kingdom.

Retrovirus-Host Interactions, The Francis Crick Institute, London, United Kingdom.

出版信息

Elife. 2019 Nov 15;8:e50256. doi: 10.7554/eLife.50256.

DOI:10.7554/eLife.50256
PMID:31729316
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6877088/
Abstract

Immune regulation is a finely balanced process of positive and negative signals. PD-L1 and its receptor PD-1 are critical regulators of autoimmune, antiviral and antitumoural T cell responses. Although the function of its predominant membrane-bound form is well established, the source and biological activity of soluble PD-L1 (sPD-L1) remain incompletely understood. Here, we show that sPD-L1 in human healthy tissues and tumours is produced by exaptation of an intronic () endogenous retroelement in the gene, encoding PD-L1, which causes omission of the transmembrane domain and the regulatory sequence in the canonical 3' untranslated region. The alternatively spliced transcript forms the major source of sPD-L1 and is highly conserved in hominids, but lost in mice and a few related species. Importantly, -encoded sPD-L1 lacks measurable T cell inhibitory activity. Instead, it functions as a receptor antagonist, blocking the inhibitory activity of PD-L1 bound on cellular or exosomal membranes.

摘要

免疫调节是正向和负向信号的精细平衡过程。PD-L1 及其受体 PD-1 是自身免疫、抗病毒和抗肿瘤 T 细胞反应的关键调节剂。尽管其主要膜结合形式的功能已经得到很好的确立,但可溶性 PD-L1(sPD-L1)的来源和生物学活性仍不完全清楚。在这里,我们表明人类健康组织和肿瘤中的 sPD-L1 是由 PD-L1 基因内含子中的内源性逆转录元件()外适应产生的,该元件导致跨膜结构域和规范的 3'非翻译区中的调节序列缺失。 剪接的 转录本形成 sPD-L1 的主要来源,在人类中高度保守,但在小鼠和一些相关物种中丢失。重要的是,编码的 sPD-L1 缺乏可测量的 T 细胞抑制活性。相反,它作为受体拮抗剂发挥作用,阻断细胞或外泌体膜上结合的 PD-L1 的抑制活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/0ced2198f6f5/elife-50256-fig6-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/f9eaf61d17f0/elife-50256-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/22d8e37e4f9a/elife-50256-fig1-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/887e2a0b099c/elife-50256-fig1-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/c31fda0b3a0a/elife-50256-fig1-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/08eb4f07c253/elife-50256-fig1-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/daab52d81b9a/elife-50256-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/909d4a507721/elife-50256-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/4bac641145f3/elife-50256-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/1815ce1357fc/elife-50256-fig3-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/3c861d36c56f/elife-50256-fig3-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/4b54b00051c8/elife-50256-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/65b020dae3b9/elife-50256-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/e96126b19a29/elife-50256-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/b9063196d79f/elife-50256-fig5-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/4400cf016dda/elife-50256-fig5-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/558f19fc7d64/elife-50256-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/0ced2198f6f5/elife-50256-fig6-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/f9eaf61d17f0/elife-50256-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/22d8e37e4f9a/elife-50256-fig1-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/887e2a0b099c/elife-50256-fig1-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/c31fda0b3a0a/elife-50256-fig1-figsupp3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/08eb4f07c253/elife-50256-fig1-figsupp4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/daab52d81b9a/elife-50256-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/909d4a507721/elife-50256-fig2-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/4bac641145f3/elife-50256-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/1815ce1357fc/elife-50256-fig3-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/3c861d36c56f/elife-50256-fig3-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/4b54b00051c8/elife-50256-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/65b020dae3b9/elife-50256-fig4-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/e96126b19a29/elife-50256-fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/b9063196d79f/elife-50256-fig5-figsupp1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/4400cf016dda/elife-50256-fig5-figsupp2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/558f19fc7d64/elife-50256-fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7696/6877088/0ced2198f6f5/elife-50256-fig6-figsupp1.jpg

相似文献

1
Soluble PD-L1 generated by endogenous retroelement exaptation is a receptor antagonist.内源性逆转录元件适应产生的可溶性 PD-L1 是一种受体拮抗剂。
Elife. 2019 Nov 15;8:e50256. doi: 10.7554/eLife.50256.
2
Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.可溶性PD-1/PD-L1及外泌体PD-L1在癌症中的生物学特性及临床意义
Front Immunol. 2022 Mar 21;13:827921. doi: 10.3389/fimmu.2022.827921. eCollection 2022.
3
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.可溶性 PD-L1 作为接受检查点阻断治疗的恶性黑色素瘤的生物标志物。
Cancer Immunol Res. 2017 Jun;5(6):480-492. doi: 10.1158/2326-6066.CIR-16-0329. Epub 2017 May 18.
4
N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1.PD-L1的N-糖基化调节靶向PD-L1和PD-1的免疫检查点阻断疗法的疗效。
Mol Cancer. 2025 May 10;24(1):140. doi: 10.1186/s12943-025-02330-w.
5
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression.一种分泌型 PD-L1 剪接变异体,可形成二聚体并介导免疫抑制。
Cancer Immunol Immunother. 2019 Mar;68(3):421-432. doi: 10.1007/s00262-018-2282-1. Epub 2018 Dec 18.
6
The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1 regulator B cells mediates immunosuppression in triple-negative breast cancer.可溶性程序性死亡配体-1(sPD-L1)与 PD-1 调节性 B 细胞之间的相互作用介导三阴性乳腺癌的免疫抑制。
Front Immunol. 2022 Jul 22;13:830606. doi: 10.3389/fimmu.2022.830606. eCollection 2022.
7
Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.程序性死亡配体1及其可溶性形式在鼻腔自然杀伤/T细胞淋巴瘤中高表达:免疫治疗的潜在理论依据。
Cancer Immunol Immunother. 2017 Jul;66(7):877-890. doi: 10.1007/s00262-017-1987-x. Epub 2017 Mar 27.
8
Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.重症肌无力患者膜结合型和可溶性诱导共刺激分子及程序性细胞死亡分子 1 的表达失衡。
Clin Immunol. 2019 Oct;207:68-78. doi: 10.1016/j.clim.2019.07.011. Epub 2019 Jul 30.
9
pH Low Insertion Peptide-Modified Programmed Cell Death-Ligand 1 Potently Suppresses T-Cell Activation Under Acidic Condition.pH 低插入肽修饰的程序性细胞死亡配体 1 在酸性条件下能有效抑制 T 细胞的激活。
Front Immunol. 2021 Dec 23;12:794226. doi: 10.3389/fimmu.2021.794226. eCollection 2021.
10
Soluble PD-L1 Concentration Is Proportional to the Expression of PD-L1 in Tissue and Is Associated with a Poor Prognosis in Esophageal Squamous Cell Carcinoma.可溶性 PD-L1 浓度与组织中 PD-L1 的表达成正比,并与食管鳞状细胞癌的不良预后相关。
Oncology. 2022;100(1):39-47. doi: 10.1159/000518740. Epub 2021 Dec 6.

引用本文的文献

1
Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs).可溶性程序性死亡配体1(sPD-L1)作为一线免疫检查点抑制剂(ICI)治疗的晚期非小细胞肺癌(NSCLC)患者持久缓解和生存的生物标志物。
Cancer Immunol Immunother. 2025 Aug 26;74(9):294. doi: 10.1007/s00262-025-04126-9.
2
Primate retroelement exonization and sexually dimorphic transcription tune type 2 immune responses.灵长类逆转录元件外显子化和性二态转录调节2型免疫反应。
Sci Immunol. 2025 Jul 4;10(109):eadr1105. doi: 10.1126/sciimmunol.adr1105.
3

本文引用的文献

1
LTR retroelement expansion of the human cancer transcriptome and immunopeptidome revealed by de novo transcript assembly.从头转录组组装揭示的人类癌症转录组和免疫肽组中的 LTR 反转录元件扩展。
Genome Res. 2019 Oct;29(10):1578-1590. doi: 10.1101/gr.248922.119. Epub 2019 Sep 19.
2
Tumor suppression of novel anti-PD-1 antibodies mediated through CD28 costimulatory pathway.新型抗 PD-1 抗体通过 CD28 共刺激途径抑制肿瘤。
J Exp Med. 2019 Jul 1;216(7):1525-1541. doi: 10.1084/jem.20182359. Epub 2019 May 23.
3
Restriction of PD-1 function by -PD-L1/CD80 interactions is required for optimal T cell responses.
Retroelement co-option disrupts the cancer transcriptional programme.
逆转录元件的借用破坏癌症转录程序。
Genome Med. 2025 May 7;17(1):48. doi: 10.1186/s13073-025-01479-9.
4
Soluble PD-L1: From Immune Evasion to Cancer Therapy.可溶性程序性死亡配体1:从免疫逃逸到癌症治疗
Life (Basel). 2025 Apr 8;15(4):626. doi: 10.3390/life15040626.
5
Endogenous retroelements in hematological malignancies: From epigenetic dysregulation to therapeutic targeting.血液系统恶性肿瘤中的内源性逆转录元件:从表观遗传失调到治疗靶点
Am J Hematol. 2025 Jan;100(1):116-130. doi: 10.1002/ajh.27501. Epub 2024 Oct 10.
6
Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications.癌症风险、预后预测及治疗应用中的可溶性免疫检查点分子
Biomark Res. 2024 Sep 2;12(1):95. doi: 10.1186/s40364-024-00647-0.
7
Trans-Regulation of Alternative mRNA Processing by CDK12 in Non-Small-Cell Lung Cancer Cells.CDK12对非小细胞肺癌细胞中可变mRNA加工的反式调控
Cells. 2023 Dec 15;12(24):2844. doi: 10.3390/cells12242844.
8
Machine learning algorithm predicts fibrosis-related blood diagnosis markers of intervertebral disc degeneration.机器学习算法预测与椎间盘退变相关的纤维化血液诊断标志物。
BMC Med Genomics. 2023 Nov 1;16(1):274. doi: 10.1186/s12920-023-01705-6.
9
Regulation of the programmed cell death protein 1/programmed cell death ligand 1 axis in relapsing-remitting multiple sclerosis.复发缓解型多发性硬化中程序性细胞死亡蛋白1/程序性细胞死亡配体1轴的调控
Brain Commun. 2023 Jul 25;5(4):fcad206. doi: 10.1093/braincomms/fcad206. eCollection 2023.
10
Regulation of PD-L1 Expression by Nuclear Receptors.核受体对 PD-L1 表达的调控。
Int J Mol Sci. 2023 Jun 8;24(12):9891. doi: 10.3390/ijms24129891.
-PD-L1/CD80 相互作用对 PD-1 功能的限制是 T 细胞最佳应答所必需的。
Science. 2019 May 10;364(6440):558-566. doi: 10.1126/science.aav7062. Epub 2019 Apr 18.
4
Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory.抑制外泌体 PD-L1 诱导全身性抗肿瘤免疫和记忆。
Cell. 2019 Apr 4;177(2):414-427.e13. doi: 10.1016/j.cell.2019.02.016.
5
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer.分泌型 PD-L1 变体介导非小细胞肺癌对 PD-L1 阻断治疗的耐药性。
J Exp Med. 2019 Apr 1;216(4):982-1000. doi: 10.1084/jem.20180870. Epub 2019 Mar 14.
6
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression.一种分泌型 PD-L1 剪接变异体,可形成二聚体并介导免疫抑制。
Cancer Immunol Immunother. 2019 Mar;68(3):421-432. doi: 10.1007/s00262-018-2282-1. Epub 2018 Dec 18.
7
Identification and characterization of an alternative cancer-derived PD-L1 splice variant.鉴定和表征一种替代性的癌症衍生 PD-L1 剪接变异体。
Cancer Immunol Immunother. 2019 Mar;68(3):407-420. doi: 10.1007/s00262-018-2284-z. Epub 2018 Dec 18.
8
Soluble immune checkpoints in cancer: production, function and biological significance.可溶性免疫检查点在癌症中的作用:产生、功能和生物学意义。
J Immunother Cancer. 2018 Nov 27;6(1):132. doi: 10.1186/s40425-018-0449-0.
9
GENCODE reference annotation for the human and mouse genomes.GENCODE 人类和小鼠基因组参考注释。
Nucleic Acids Res. 2019 Jan 8;47(D1):D766-D773. doi: 10.1093/nar/gky955.
10
Increased Soluble PD-L1 Levels in the Plasma of Patients with Epithelial Ovarian Cancer Correlate with Plasma Levels of and .上皮性卵巢癌患者血浆中可溶性程序性死亡配体1(sPD-L1)水平升高与血浆中[具体物质1]和[具体物质2]水平相关。
Anticancer Res. 2018 Oct;38(10):5739-5745. doi: 10.21873/anticanres.12912.